Proactiveinvestors Australia Dynavax Technologies https://www.proactiveinvestors.com.au Proactiveinvestors Australia Dynavax Technologies RSS feed en Tue, 23 Jul 2019 12:52:36 +1000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - Dynavax shares set to rise on "encouraging' results of cancer drug ]]> https://www.proactiveinvestors.com.au/companies/news/195061/dynavax-shares-set-to-rise-on-encouraging-results-of-cancer-drug-195061.html Shares of Dynavax Technologies Corp. (NASDAQ:DVAX) are set to climb after the company reported its immune-oncology drug showed “promising” response rate in treating head and neck cancers.

The stock rose 14% to US$22.44 in pre-market trading.

Dynavax released data in an abstract at the American Association for Cancer research meeting.

The SD-101 drug “showed a promising 40%” overall response rate “indicative of potential activity in the difficult-to-treat setting of head and neck cancers,” MarketWatch reported, citing RBC Capital Markets analyst Brian Abrahams.

 

 

 

]]>
Mon, 16 Apr 2018 09:28:00 +1000 https://www.proactiveinvestors.com.au/companies/news/195061/dynavax-shares-set-to-rise-on-encouraging-results-of-cancer-drug-195061.html
<![CDATA[News - Dynavax shares skyrocket after its Hepatitis B drug gets US FDA advisory committee approval ]]> https://www.proactiveinvestors.com.au/companies/news/181717/dynavax-shares-skyrocket-after-its-hepatitis-b-drug-gets-us-fda-advisory-committee-approval-181717.html Dynavax Technologies Corp. (NYSE:DVAX) shares jumped 88% in premarket trade Monday after a US Food and Drug Administration (FDA) advisory committee said the safety data for its Hepatitis B vaccination supported its approval.

The advisory committee voted 12 to 1 on the safety data, with three members abstaining.

A previous advisory committee had voted 13 to 1 in favor of the vaccine's ability to promote an immune response.

On Monday, Dynavax was upgraded to overweight at J.P. Morgan with a US$27 price target and upgraded to outperform at RBC Capital Markets with a US$26 price target.

Although there are already Hepatitis B vaccines in the market, they require three doses administered over six months, while Dynavax's HEPLISAV-B vaccine only requires two doses over a month period, the company said.

An FDA decision on the approval of the vaccine is expected by August 10.

Dynavax said should the vaccine be given the green light, it will seek a recommendation from the CDC's immunization practices advisory committee.

The company plans a commercial launch of the vaccine in early 2018 "on its own or through a commercial partner."

Dynavax shares have surged 88.11% to $17.40 in premarket trade and then later gained 76% to $16.37 each.

]]>
Mon, 31 Jul 2017 13:58:00 +1000 https://www.proactiveinvestors.com.au/companies/news/181717/dynavax-shares-skyrocket-after-its-hepatitis-b-drug-gets-us-fda-advisory-committee-approval-181717.html